Evoke Pharma, Inc. (EVOK) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EVOK Revenue Growth
Revenue Breakdown (FY 2024)
EVOK's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
EVOK Revenue Analysis (2013–2024)
As of May 8, 2026, Evoke Pharma, Inc. (EVOK) generated trailing twelve-month (TTM) revenue of $14.4 million, reflecting explosive growth of +61.4% year-over-year. The most recent quarter (Q3 2025) recorded $4.3 million in revenue, up 14.2% sequentially.
Looking at the longer-term picture, EVOK's historical revenue data shows a 3-year CAGR of +85.0%. The company achieved its highest annual revenue of $10.2 million in 2024, representing a new all-time high.
Revenue diversification analysis shows EVOK's business is primarily driven by Pharmaceutical Products (100%). With over half of revenue concentrated in Pharmaceutical Products, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRPO (+23.6% YoY), AYTU (-3.3% YoY), and ANIP (+43.8% YoY), EVOK has outperformed the peer group in terms of revenue growth. Compare EVOK vs PRPO →
EVOK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVOKCurrent | $14M | +61.4% | - | -50.8% | |
 PRPO | $16M | +23.6% | +38.6% | -26.4% | |
 AYTU | $66M | -3.3% | +19.2% | -11.8% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% |
EVOK Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.2M | +97.8% | $9.9M | 96.5% | $-5,204,137 | -50.8% |
| 2023 | $5.2M | +106.5% | $5.0M | 96.1% | $-7,430,891 | -143.4% |
| 2022 | $2.5M | +55.0% | $2.1M | 85.2% | $-7,786,137 | -310.4% |
| 2021 | $1.6M | +6929.0% | $1.3M | 79.7% | $-8,151,647 | -503.8% |
| 2020 | $23K | - | $-63,692 | -276.7% | $-13,047,349 | -56678.3% |
| 2019 | $0 | - | $0 | - | $-7,154,453 | - |
| 2018 | $0 | - | $0 | - | $-8,014,685 | - |
| 2017 | $0 | - | $0 | - | $-11,230,682 | - |
| 2016 | $0 | - | $0 | - | $-10,544,425 | - |
| 2015 | $0 | - | $0 | - | $-11,818,303 | - |
See EVOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVOK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVOK — Frequently Asked Questions
Quick answers to the most common questions about buying EVOK stock.
Is EVOK's revenue growth accelerating or slowing?
EVOK revenue is accelerating at +61.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $14M. Growth momentum has increased versus prior periods.
What is EVOK's long-term revenue growth rate?
Evoke Pharma, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +61.4% is above this long-term average.
How is EVOK's revenue distributed by segment?
EVOK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.